Global Diabetic Assays Market – Industry Trends and Forecast to 2031

Diabetic Assays Market Analysis and Size

Diabetic assays market continues to advance with cutting-edge technologies, enhancing accuracy and efficiency in diabetes diagnosis and management. The latest methods, such as automated immunoassays and point-of-care testing are transforming patient care, providing quicker results and reducing healthcare costs. This growth is fueled by increasing diabetic cases globally, driving innovation and adoption of next-generation diagnostic tools in healthcare systems worldwide. For instance, the United Nation anticipated that 1 out of 5 diabetes patients are above 65 years old in 2017. The increasing diabetes cases among the elderly population in U.S. is leading the market growth.                              

The global diabetic assays market size was valued at USD 3.38 billion in 2023 and is projected to reach USD 4.80 billion by 2031, with a CAGR of 4.50% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Diabetic assays refer to diagnostic tests used to measure various biomarkers related to diabetes, such as blood glucose levels, insulin, and glycated hemoglobin (HbA1c). These assays are critical for diagnosing diabetes, monitoring treatment effectiveness, and assessing overall glucose metabolism. They involve techniques such as immunoassays, enzymatic assays, and chromatography to quantify these biomarkers accurately in clinical settings.          

Diabetic Assays Market Dynamics

Drivers

• Rising Diabetes Prevalence

The increasing global prevalence of diabetes is a significant driver for the diagnostic assays market. As diabetes rates rise worldwide, there is a corresponding surge in demand for advanced diagnostic assays to accurately monitor blood glucose levels and assess diabetes-related biomarkers. For instance, in 2023, the International Diabetes Federation reported over 500 million people living with diabetes globally, highlighting the urgent need for effective diagnostic tools to manage and treat this chronic condition, thereby driving market growth.

• Rising Demand for Point-of-Care Testing (POCT)

The rising demand for Point-of-Care Testing (POCT) is a significant driver of growth in the diabetic assays market. POCT meets the increasing need for rapid results and decentralized testing, improving patient outcomes and healthcare efficiency. For instance, glucose monitoring devices such as Abbott's FreeStyle Libre provide real-time glucose readings, empowering patients to manage diabetes more effectively without traditional laboratory visits. This trend towards convenience and immediacy is fueling market expansion globally.

Opportunities

• Increasing IT Integration in Diabetic Assays

Increasing IT integration systems is transforming the diabetic assays market by enhancing diagnostic capabilities and efficiency. For instance, cloud-based platforms enable real-time data access, improving patient monitoring and treatment management. Electronic health records (EHR) integration ensures seamless information flow among healthcare providers, optimizing care coordination. Furthermore, telemedicine advancements enable remote consultations and data-driven insights, empowering healthcare professionals to deliver personalized diabetes management strategies. These digital innovations drive market growth by improving diagnostic accuracy and patient outcomes.

• Advancement in Technology

Technological advancements in diabetic assays, such as biosensors and rapid testing methods, significantly enhance accuracy and convenience, driving market growth. For instance, continuous glucose monitoring (CGM) systems such as Abbott's FreeStyle Libre use biosensor technology to provide real-time glucose readings without the need for fingerstick tests. These innovations not only improve patient compliance but also support healthcare providers in managing diabetes more effectively, thus expanding the diabetic assays market globally.

Restraints/Challenges

• High Development Costs

High development costs associated with research, clinical trials, and regulatory submissions for diabetic assays deter smaller companies from entering the market and limit innovation. These financial barriers restrict competition and potentially stifle advancements in assay technologies. As a result, the market may lack diversity in products and pricing strategies, hindering overall market growth and the ability to meet evolving healthcare needs effectively. 

• Limited Healthcare Infrastructure

Limited healthcare infrastructure in developing regions restricts diabetic assay adoption due to inadequate diagnostic facilities, healthcare professional training, and reimbursement policies. These challenges impede market growth by limiting access to essential testing and hindering effective management of diabetes through diagnostics. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In February 2020, Abbott (US) received US FDA approval for the FreeStyle Libre 14-day Flash glucose monitoring systems for hospital use, enhancing glucose monitoring capabilities in clinical settings
• Also in February 2020, Insulet (US) entered a commercialization agreement with DexCom, Inc. (US) to integrate its current and future CGM systems with DexCom's OMNIPOD Horizon tubeless insulin pump system
• In April 2020, Ypsomed (Switzerland) partnered with DexCom, Inc. (US) to integrate mylife YpsoPump data with DexCom's G6 CGM sensors, aiming to develop a hybrid closed-loop solution for diabetes management
• In January 2020, LifeScan (US) collaborated with DKSH to enhance marketing, sales, regulatory services, and distribution of LifeScan products across Southeast Asia, Hong Kong, and Taiwan, focusing on improving diabetes care access

Diabetic Assays Market Scope

The market is segmented on the basis of method, product type, disease type, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Method

• ELISA
• Point of Care Testing
• Enzymatic Assay
• Colorimetric Assay
• Others

 Product Type

• Instruments
• Testing Kits
• Reagent

 Disease Type

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

  End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Diabetic Assays Market Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, method, product type, disease type, end-users and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to show significant growth in the diabetic assays market due to increasing diabetes prevalence in the U.S. This necessitates higher demand for assays to detect and identify diabetes cases, driving market expansion throughout the forecasted period.

Asia-Pacific is expected to dominate the diabetic assays market due to its emerging economic conditions and increased vendor investments. These factors facilitate widespread development of diabetes assays, catering to the region's growing healthcare demands and technological advancements. The region's proactive approach positions it as a pivotal player in advancing diabetes diagnostics and management solutions globally.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Diabetic Assays Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Abbvie, Inc (U.S.)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd (Israel)
• Pfizer Inc. (U.S.)
• Merck KGaA (U.S.)
• Abbott (U.S.)
• Siemens Healthcare Private Limited (Germany)
• Dynatronics Corporation (U.S.)
• BIOMÉRIEUX (France)
•  Bio-Rad Laboratories, Inc. (U.S.)
• BAG Diagnostics GmbH (Germany)
• DiaSorin S.p.A. (Italy)
• DRG INSTRUMENTS GMBH (Germany)
• PTS Diagnostics (U.S.)
• Ortho Clinical Diagnostics (U.S.)
• Diazyme Laboratories, Inc. (U.S.)
• ETHOS BIOSCIENCES (U.S.)
• Abnova Corporation (Taiwan)
• Monobind Inc. (U.S.)

SKU-47754